Remedy Plan Therapeutics
June 16, 2025
Company Presentation
Oncology
Remedy Plan Therapeutics is a privately held, clinical-stage pharmaceutical company transforming the field of NAMPT inhibition, with a pipeline of novel, hyperbolic NAMPT inhibitors, that never fully turn activity off. RPT1G’s novel hyperbolic inhibition mechanism of action solves the on-target toxicity seen with many previous NAMPT inhibitor programs (e.g. AbbVie, Lilly, Astellas, and Genentech). Remedy Plan's novel NAMPT inhibitors have broad therapeutic applications in cancer, autoimmune and metabolic diseases. Their lead asset is currently in a Phase 1 trial in healthy volunteers and will be advancing into oncology later this year.
Company HQ City:
Gaithersburg
Company HQ State:
MD
Company HQ Country:
United States
Year Founded:
2016
Lead Product in Development:
RPT1G is a first-in-class hyperbolic NAMPT inhibitor that avoids on target toxicity observed by all previous complete NAMPT inhibitors. RPT1G has a full preclinical package and robust mechanistic studies that demonstrate its highly differentiated mechanism of action. A healthy volunteer study with RPT1G was initiated in November 2024 and is expected to be completed in Q2 2025. RPT1G will be advancing into oncology later this year.
CEO
Gregory Crimmins
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
Open to discussing partnership for the co-development of our pipeline of NAMPT inhibitors.
When you expect your next catalyst update?
Completion of healthy volunteer study
What is your next catalyst (value inflection) update?
May 2025
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}